ONC || Melanoma & Skin Cancers

CheckMate 067 ends ipilimumab’s reign in first-line metastatic melanoma

Posted on: 01/06/2015 - 18:29

CHICAGO – Nivolumab and nivolumab plus ipilimumab are superior to ipilimumab alone in first-line metastatic melanoma, results from the phase III CheckMate 067 study suggest. After a minimum of 9...

Field of Interest: Dermatology

Type: News Item

CheckMate 067 ends ipilimumab’s reign in first-line metastatic melanoma

Posted on: 01/06/2015 - 18:29

CHICAGO – Nivolumab and nivolumab plus ipilimumab are superior to ipilimumab alone in first-line metastatic melanoma, results from the phase III CheckMate 067 study suggest. After a minimum of 9...

Field of Interest: Oncology

Type: News Item

VIDEO: Dual immunotherapy more powerful in melanoma, but where do we go from here?

Posted on: 01/06/2015 - 17:30

CHICAGO – Combining the immunotherapy antibodies nivolumab and ipilimumab induced more robust responses in untreated advanced melanoma when used together than as single agents, according to phase III...

Field of Interest: Oncology

Type: News Item

CheckMate 067 ends ipilimumab’s reign in first-line metastatic melanoma

CheckMate 067 ends ipilimumab’s reign in first-line metastatic melanoma

VIDEO: Dual immunotherapy more powerful in melanoma, but where do we go from here?

Newsletters

Latest Newsletters

You are here

ONC || Melanoma & Skin Cancers

CheckMate 067 ends ipilimumab’s reign in first-line metastatic melanoma

CheckMate 067 ends ipilimumab’s reign in first-line metastatic melanoma

VIDEO: Dual immunotherapy more powerful in melanoma, but where do we go from here?

Newsletters

Latest Newsletters